S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
Israel hails 'success' in blocking Iran's unprecedented attack. Biden now seeks diplomatic response
Germany's Scholz arrives in China on a visit marked by trade tensions and Ukraine conflict
Diplomat tapped as Latvia's new foreign minister as incumbent quits following flights scandal
India's Modi vows to boost social spending, make country into a manufacturing hub ahead of election
Can homeless people be fined for sleeping outside? A rural Oregon city asks the US Supreme Court
The craze for Masters gnomes is growing. Little golf-centric statue is now a coveted collector item
Olympic track uniforms spark online debate about who designed them and why they're so skimpy
S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
Israel hails 'success' in blocking Iran's unprecedented attack. Biden now seeks diplomatic response
Germany's Scholz arrives in China on a visit marked by trade tensions and Ukraine conflict
Diplomat tapped as Latvia's new foreign minister as incumbent quits following flights scandal
India's Modi vows to boost social spending, make country into a manufacturing hub ahead of election
Can homeless people be fined for sleeping outside? A rural Oregon city asks the US Supreme Court
The craze for Masters gnomes is growing. Little golf-centric statue is now a coveted collector item
Olympic track uniforms spark online debate about who designed them and why they're so skimpy
S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
Israel hails 'success' in blocking Iran's unprecedented attack. Biden now seeks diplomatic response
Germany's Scholz arrives in China on a visit marked by trade tensions and Ukraine conflict
Diplomat tapped as Latvia's new foreign minister as incumbent quits following flights scandal
India's Modi vows to boost social spending, make country into a manufacturing hub ahead of election
Can homeless people be fined for sleeping outside? A rural Oregon city asks the US Supreme Court
The craze for Masters gnomes is growing. Little golf-centric statue is now a coveted collector item
Olympic track uniforms spark online debate about who designed them and why they're so skimpy
S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
Israel hails 'success' in blocking Iran's unprecedented attack. Biden now seeks diplomatic response
Germany's Scholz arrives in China on a visit marked by trade tensions and Ukraine conflict
Diplomat tapped as Latvia's new foreign minister as incumbent quits following flights scandal
India's Modi vows to boost social spending, make country into a manufacturing hub ahead of election
Can homeless people be fined for sleeping outside? A rural Oregon city asks the US Supreme Court
The craze for Masters gnomes is growing. Little golf-centric statue is now a coveted collector item
Olympic track uniforms spark online debate about who designed them and why they're so skimpy

Onconova Therapeutics (ONTX) Competitors

ONTX vs. KALA, SYBX, INDP, BIOR, TLPH, LUMO, ALLR, FLGC, GLTO, and VINC

Should you be buying Onconova Therapeutics stock or one of its competitors? The main competitors of Onconova Therapeutics include KALA BIO (KALA), Synlogic (SYBX), Indaptus Therapeutics (INDP), Biora Therapeutics (BIOR), Talphera (TLPH), Lumos Pharma (LUMO), Allarity Therapeutics (ALLR), Flora Growth (FLGC), Galecto (GLTO), and Vincerx Pharma (VINC). These companies are all part of the "pharmaceutical preparations" industry.

Onconova Therapeutics vs.

KALA BIO (NASDAQ:KALA) and Onconova Therapeutics (NASDAQ:ONTX) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, risk, profitability, dividends, earnings, media sentiment and community ranking.

KALA BIO has a net margin of 0.00% compared to KALA BIO's net margin of -8,930.97%. KALA BIO's return on equity of -95.43% beat Onconova Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
KALA BION/A -281.02% -65.57%
Onconova Therapeutics -8,930.97%-95.43%-61.19%

KALA BIO has a beta of -1.85, suggesting that its share price is 285% less volatile than the S&P 500. Comparatively, Onconova Therapeutics has a beta of 1.38, suggesting that its share price is 38% more volatile than the S&P 500.

24.6% of KALA BIO shares are held by institutional investors. Comparatively, 8.0% of Onconova Therapeutics shares are held by institutional investors. 13.4% of KALA BIO shares are held by insiders. Comparatively, 3.3% of Onconova Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

KALA BIO presently has a consensus price target of $18.00, suggesting a potential upside of 150.00%. Onconova Therapeutics has a consensus price target of $11.00, suggesting a potential upside of ∞. Given KALA BIO's higher probable upside, analysts clearly believe Onconova Therapeutics is more favorable than KALA BIO.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
KALA BIO
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
3.00
Onconova Therapeutics
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00

Onconova Therapeutics has lower revenue, but higher earnings than KALA BIO. KALA BIO is trading at a lower price-to-earnings ratio than Onconova Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
KALA BIO$3.89M5.22-$42.20M-$17.94-0.40
Onconova Therapeutics$230K0.00-$18.96M-$0.91N/A

Onconova Therapeutics received 85 more outperform votes than KALA BIO when rated by MarketBeat users. However, 66.59% of users gave KALA BIO an outperform vote while only 59.78% of users gave Onconova Therapeutics an outperform vote.

CompanyUnderperformOutperform
KALA BIOOutperform Votes
297
66.59%
Underperform Votes
149
33.41%
Onconova TherapeuticsOutperform Votes
382
59.78%
Underperform Votes
257
40.22%

In the previous week, KALA BIO had 3 more articles in the media than Onconova Therapeutics. MarketBeat recorded 6 mentions for KALA BIO and 3 mentions for Onconova Therapeutics. Onconova Therapeutics' average media sentiment score of 0.43 beat KALA BIO's score of 0.29 indicating that KALA BIO is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
KALA BIO
0 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Neutral
Onconova Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Summary

KALA BIO beats Onconova Therapeutics on 9 of the 16 factors compared between the two stocks.

Get Onconova Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for ONTX and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ONTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ONTX vs. The Competition

MetricOnconova TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$20.90M$6.50B$4.93B$7.66B
Dividend YieldN/A3.08%2.94%3.93%
P/E Ratio-1.097.01169.0014.19
Price / SalesN/A333.102,415.6094.92
Price / CashN/A31.0736.9131.12
Price / BookN/A5.104.624.29
Net Income-$18.96M$142.96M$104.49M$214.71M

Onconova Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
KALA
KALA BIO
4.0826 of 5 stars
$7.40
-2.9%
$18.00
+143.2%
-59.6%$20.87M$3.89M-0.4134Short Interest ↓
News Coverage
SYBX
Synlogic
2.1747 of 5 stars
$1.80
+3.4%
$65.00
+3,511.1%
-82.6%$20.97M$3.37M-0.176Short Interest ↑
INDP
Indaptus Therapeutics
1.8182 of 5 stars
$2.46
+3.4%
$12.00
+387.8%
+52.2%$21.01MN/A-1.347News Coverage
Gap Up
BIOR
Biora Therapeutics
0.7203 of 5 stars
$0.70
-4.1%
N/A-74.2%$21.22M$4,000.00-0.0854Short Interest ↑
Analyst Revision
Gap Down
TLPH
Talphera
1.9791 of 5 stars
$1.20
+2.6%
$6.00
+400.0%
N/A$20.36M$650,000.00-0.8115
LUMO
Lumos Pharma
2.2023 of 5 stars
$2.69
+1.5%
$18.00
+569.1%
-23.0%$21.82M$2.05M-0.6433
ALLR
Allarity Therapeutics
0.2922 of 5 stars
$3.59
-16.5%
N/A-99.8%$22.19MN/A0.005Stock Split
Short Interest ↓
High Trading Volume
FLGC
Flora Growth
2.6912 of 5 stars
$2.17
-4.4%
$7.00
+222.6%
-59.6%$19.49M$76.07M-0.22337Insider Buying
Short Interest ↑
Gap Down
GLTO
Galecto
1.3912 of 5 stars
$0.71
flat
$5.33
+646.5%
-62.4%$19.37MN/A-0.4913Short Interest ↑
VINC
Vincerx Pharma
2.5998 of 5 stars
$1.06
-77.8%
$5.00
+371.7%
-2.0%$22.70MN/A-0.5641Analyst Report
High Trading Volume

Related Companies and Tools

This page (NASDAQ:ONTX) was last updated on 4/14/2024 by MarketBeat.com Staff

From Our Partners